Circulating biomarkers are a promising beacon for diagnosing cancer or detecting early signs of treatment resistance or metastasis. Daniel Hayes, M.D., Stuart B. Padnos Professor of Breast Cancer Research at Rogel, discusses the varying stances by professionals on the matter and how this technique could be good or bad in patient diagnosis.
